Physician profile
Parham Eftekhari
NPI 1922285998
$22,373.74
in general payments reported to CMS, 2019-2025
30 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,238 · 2020: $1,070 · 2021: $1,227 · 2022: $1,646 · 2023: $1,190 · 2024: $1,575 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $5,311 · Education: $53.31 · Travel and Lodging: $43.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,785.00 |
| Food and Beverage | $5,310.76 |
| Education | $53.31 |
| Travel and Lodging | $43.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,413.78 | 2023-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $2,342.48 | 2019-2025 | Farxiga, Lokelma, Flumist Quadrivalent |
| Lilly USA, LLC | $982.85 | 2023-2025 | Jardiance |
| Amgen INC. | $865.47 | 2019-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $736.21 | 2022-2025 | Filspari |
| Vifor Pharma, INC. | $711.03 | 2019-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $692.68 | 2020-2025 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $585.68 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $509.45 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $502.71 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $414.37 | 2021-2024 | |
| Glaxosmithkline, LLC. | $389.12 | 2020-2025 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $375.83 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $367.83 | 2019-2025 | Rayaldee |
| Calliditas Therapeutics US INC. | $295.15 | 2022-2025 | Tarpeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $277.91 | 2022-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $237.90 | 2019-2025 | Vafseo, Auryxia |
| Baxter Healthcare | $178.82 | 2019-2020 | |
| Abbott Laboratories | $98.68 | 2020 | |
| Alexion Pharmaceuticals, INC. | $61.45 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $48.95 | 2019 | |
| Fresenius USA Marketing, INC. | $44.52 | 2020-2021 | |
| Genzyme Corporation | $41.13 | 2019 | |
| Shire North American Group INC | $39.90 | 2019 | |
| Amicus Therapeutics, INC. | $38.52 | 2022 | |
| Novo Nordisk INC | $30.25 | 2025 | Ozempic |
| Alnylam Pharmaceuticals INC. | $25.45 | 2023 | Oxlumo |
| Ardelyx, INC. | $25.00 | 2025 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $23.97 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $16.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parham Eftekhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.